"Point of no return" in unilateral renal ischemia reperfusion injury in mice.


Journal

Journal of biomedical science
ISSN: 1423-0127
Titre abrégé: J Biomed Sci
Pays: England
ID NLM: 9421567

Informations de publication

Date de publication:
14 Feb 2020
Historique:
received: 10 07 2019
accepted: 23 01 2020
entrez: 16 2 2020
pubmed: 16 2 2020
medline: 14 8 2020
Statut: epublish

Résumé

In the past years evidence has been growing about the interconnection of chronic kidney disease and acute kidney injury. The underlying pathophysiological mechanisms remain unclear. We hypothesized, that a threshold ischemia time in unilateral ischemia/reperfusion injury sets an extent of ischemic tubule necrosis, which as "point of no return" leads to progressive injury. This progress is temporarily associated by increased markers of inflammation and results in fibrosis and atrophy of the ischemic kidney. Acute tubule necrosis was induced by unilateral ischemia/reperfusion injury in male C57BL/6 N mice with different ischemia times (15, 25, 35, and 45 min). At multiple time points between 15 min and 5 weeks we assessed gene expression of markers for injury, inflammation, and fibrosis, histologically the injury of tubules, cell death (TUNEL), macrophages, neutrophil influx and kidney atrophy. Unilateral ischemia for 15 and 25 min induced upregulation of markers for injury after reperfusion for 24 h but no upregulation after 5 weeks. None of the markers for inflammation or fibrosis were upregulated after ischemia for 15 and 25 min at 24 h or 5 weeks on a gene expression level, except for Il-6. Ischemia for 35 and 45 min consistently induced upregulation of markers for inflammation, injury, and partially of fibrosis (Tgf-β1 and Col1a1) at 24 h and 5 weeks. The threshold ischemia time for persistent injury of 35 min induced a temporal association of markers for inflammation and injury with peaks between 6 h and 7 d along the course of 10 d. This ischemia time also induced persistent cell death (TUNEL) throughout observation for 5 weeks with a peak at 6 h and progressing kidney atrophy beginning 7 d after ischemia. This study confirms the evidence of a threshold extent of ischemic injury in which markers of injury, inflammation and fibrosis do not decline to baseline but remain upregulated assessed in long term outcome (5 weeks). Excess of this threshold as "point of no return" leads to persistent cell death and progressing atrophy and is characterized by a temporal association of markers for inflammation and injury.

Sections du résumé

BACKGROUND BACKGROUND
In the past years evidence has been growing about the interconnection of chronic kidney disease and acute kidney injury. The underlying pathophysiological mechanisms remain unclear. We hypothesized, that a threshold ischemia time in unilateral ischemia/reperfusion injury sets an extent of ischemic tubule necrosis, which as "point of no return" leads to progressive injury. This progress is temporarily associated by increased markers of inflammation and results in fibrosis and atrophy of the ischemic kidney.
METHODS METHODS
Acute tubule necrosis was induced by unilateral ischemia/reperfusion injury in male C57BL/6 N mice with different ischemia times (15, 25, 35, and 45 min). At multiple time points between 15 min and 5 weeks we assessed gene expression of markers for injury, inflammation, and fibrosis, histologically the injury of tubules, cell death (TUNEL), macrophages, neutrophil influx and kidney atrophy.
RESULTS RESULTS
Unilateral ischemia for 15 and 25 min induced upregulation of markers for injury after reperfusion for 24 h but no upregulation after 5 weeks. None of the markers for inflammation or fibrosis were upregulated after ischemia for 15 and 25 min at 24 h or 5 weeks on a gene expression level, except for Il-6. Ischemia for 35 and 45 min consistently induced upregulation of markers for inflammation, injury, and partially of fibrosis (Tgf-β1 and Col1a1) at 24 h and 5 weeks. The threshold ischemia time for persistent injury of 35 min induced a temporal association of markers for inflammation and injury with peaks between 6 h and 7 d along the course of 10 d. This ischemia time also induced persistent cell death (TUNEL) throughout observation for 5 weeks with a peak at 6 h and progressing kidney atrophy beginning 7 d after ischemia.
CONCLUSIONS CONCLUSIONS
This study confirms the evidence of a threshold extent of ischemic injury in which markers of injury, inflammation and fibrosis do not decline to baseline but remain upregulated assessed in long term outcome (5 weeks). Excess of this threshold as "point of no return" leads to persistent cell death and progressing atrophy and is characterized by a temporal association of markers for inflammation and injury.

Identifiants

pubmed: 32059667
doi: 10.1186/s12929-020-0623-9
pii: 10.1186/s12929-020-0623-9
pmc: PMC7023741
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : AN372/14-3
Organisme : Deutsche Forschungsgemeinschaft
ID : AN372/23-1
Organisme : Deutsche Forschungsgemeinschaft
ID : AN372/24-1

Références

Nephrol Dial Transplant. 2002 Dec;17(12):2145-52
pubmed: 12454225
Biochim Biophys Acta. 2013 Jul;1832(7):989-97
pubmed: 23246690
Semin Nephrol. 2010 May;30(3):268-77
pubmed: 20620671
Chem Biol Interact. 2018 Jun 1;289:40-46
pubmed: 29704511
Age (Dordr). 2011 Mar;33(1):89-99
pubmed: 20635153
BMC Nephrol. 2016 Sep 20;17(1):133
pubmed: 27649757
J Clin Invest. 2002 Oct;110(8):1083-91
pubmed: 12393844
Am J Pathol. 1989 Sep;135(3):509-15
pubmed: 2782382
JCI Insight. 2019 Jan 24;4(2):
pubmed: 30674725
J Am Soc Nephrol. 2008 Jun;19(6):1106-15
pubmed: 18337485
J Clin Invest. 2014 Jun;124(6):2299-306
pubmed: 24892703
Cell Death Dis. 2011 Nov 17;2:e230
pubmed: 22089168
Nat Commun. 2018 Apr 9;9(1):1344
pubmed: 29632300
J Am Soc Nephrol. 2006 Jun;17(6):1503-20
pubmed: 16707563
Nephrol Dial Transplant. 2009 Nov;24(11):3265-8
pubmed: 19318357
Nephrol Dial Transplant. 2008 Jul;23(7):2126-8
pubmed: 18587158
Fibrogenesis Tissue Repair. 2014 Mar 28;7(1):4
pubmed: 24678881
N Engl J Med. 2015 Mar 19;372(12):1138-49
pubmed: 25785971
Kidney Int. 2009 Nov;76(10):1089-97
pubmed: 19741590
Mol Cell Biochem. 2016 May;416(1-2):109-16
pubmed: 27084535
Sci Transl Med. 2019 Jan 23;11(476):
pubmed: 30674655
Kidney Int. 2008 Dec;74(12):1526-37
pubmed: 18843253
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
J Am Soc Nephrol. 2014 Feb;25(2):292-304
pubmed: 24309188
J Am Soc Nephrol. 2003 Oct;14(10):2503-15
pubmed: 14514728
Physiol Rep. 2018 May;6(10):e13707
pubmed: 29845768
J Am Soc Nephrol. 2017 Jun;28(6):1753-1768
pubmed: 28073931
Cell Death Differ. 2019 Jan;26(1):83-98
pubmed: 30201975
Contrib Nephrol. 2010;165:39-45
pubmed: 20427954
J Am Soc Nephrol. 2008 Mar;19(3):547-58
pubmed: 18235097
PLoS One. 2016 Feb 18;11(2):e0149489
pubmed: 26890071
Nat Rev Immunol. 2014 Nov;14(11):759-67
pubmed: 25324125
Transl Res. 2012 Oct;160(4):291-7
pubmed: 22683419
Nephrol Dial Transplant. 2006 Mar;21(3):605-15
pubmed: 16282336
Nephrol Dial Transplant. 2008 Mar;23(3):842-52
pubmed: 17984109
J Am Soc Nephrol. 2001 Jun;12(6):1173-87
pubmed: 11373340
Biochem Pharmacol. 2013 Feb 15;85(4):570-82
pubmed: 23291264
J Nephrol. 2012 Sep-Oct;25(5):738-43
pubmed: 22180224
Kidney Int. 2011 Jun;79(12):1361-9
pubmed: 21430640
J Am Assoc Lab Anim Sci. 2007 Sep;46(5):37-41
pubmed: 17877326
Semin Nephrol. 1998 Sep;18(5):498-504
pubmed: 9754602
Acta Med Indones. 2012 Jul;44(3):246-55
pubmed: 22983082
FASEB J. 2004 May;18(7):816-27
pubmed: 15117886
J Am Soc Nephrol. 2016 Jan;27(1):27-39
pubmed: 26334031
Nephron. 2002 Jun;91(2):262-9
pubmed: 12053063
J Am Soc Nephrol. 2007 Oct;18(10):2704-14
pubmed: 17898236
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Front Physiol. 2015 Mar 19;6:82
pubmed: 25852569
J Am Soc Nephrol. 2009 Jan;20(1):223-8
pubmed: 19020007
Mod Pathol. 2012 Jun;25(6):859-68
pubmed: 22343787

Auteurs

Alexander Holderied (A)

Department of Nephrology and Medical Intensive Care, Charité, Universitätsmedizin Berlin, Berlin, Germany. Alexander.Holderied@charite.de.

Franziska Kraft (F)

Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, Munich, Germany.

Julian Aurelio Marschner (JA)

Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, Munich, Germany.

Marc Weidenbusch (M)

Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, Munich, Germany.

Hans-Joachim Anders (HJ)

Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, Munich, Germany.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH